(Q34498105)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11796232%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

review article

1 reference

title

Novel approaches to the treatment of non-small cell lung cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11796232%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11796232%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

Carlos G Ferreira

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11796232%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

Cynthia Huisman

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11796232%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

publication date

1 January 2002

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11796232%20AND%20SRC:MED&resulttype=core&format=json

Critical Reviews in Oncology Hematology

6 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11796232%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11796232%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11796232%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

page(s)

57-77

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11796232%20AND%20SRC:MED&resulttype=core&format=json

A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer.

6 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Effects of Vinorelbine on Quality of Life and Survival of Elderly Patients With Advanced Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC).

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Single-agent gemcitabine: an active and better tolerated alternative to standard cisplatin-based chemotherapy in locally advanced or metastatic non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group. Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

What Is the Evidence That Tumors Are Angiogenesis Dependent?

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Antiangiogenesis for cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Prognostic significance of tumoral angiogenesis in completely resected late stage lung carcinoma (stage IIIA-N2). Impact of adjuvant therapies in a subset of patients at high risk of recurrence

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Prognostic significance of platelet and microvessel counts in operable non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Microvessel count predicts metastatic disease and survival in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Angiogenesis as a Prognostic Indicator of Survival in Non-Small-Cell Lung Carcinoma: a Prospective Study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

PROGNOSTIC VALUE OF ANGIOGENESIS IN OPERABLE NON-SMALL CELL LUNG CANCER

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Angiogenesis and molecular biologic substaging in patients with stage I non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Relation of neovascularisation to metastasis of non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Tumor angiogenesis as a prognostic marker in operable non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Tumor angiogenesis in human lung adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Angiogenesis as a predictor of survival after surgical resection for stage I non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Expression of vascular endothelial growth factor mRNA in non-small-cell lung carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Vascular endothelial growth factor expression in non-small-cell lung cancer: prognostic significance in squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Tumor angiogenesis and recurrence in stage I non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

The basic fibroblast growth factor and its receptor in pulmonary adenocarcinomas: an investigation of their expression as prognostic markers

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Immunocytochemical markers in stage I lung cancer: relevance to prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Thrombocytes are the major source for soluble vascular endothelial growth factor in peripheral blood

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Endostatin: an endogenous inhibitor of angiogenesis and tumor growth

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Vascular endothelial growth factor increased by pulmonary surgery accelerates the growth of micrometastases in metastatic lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Antitumor activity of thalidomide in refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Matrix metalloproteinases: biologic activity and clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Matrix metalloproteinase inhibitors: applications in oncology.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Changing views of the role of matrix metalloproteinases in metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small-cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Expression of matrix metalloproteinase (gelatinase) in T1 adenocarcinoma of the lung

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Expression of type IV collagenase correlates with the expression of vascular endothelial growth factor in primary non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Activation of the precursor of gelatinase A/72 kDa type IV collagenase/MMP-2 in lung carcinomas correlates with the expression of membrane-type matrix metalloproteinase (MT-MMP) and with lymph node metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Expression of matrix metalloproteinases and tissue inhibitor of matrix metalloproteinases in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Expression of matrix metalloproteinases and their inhibitors in human bronchopulmonary carcinomas: quantificative and morphological analyses

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Association of expression of metalloproteinases and their inhibitors with the metastatic potential of squamous-cell lung carcinomas. A molecular and immunohistochemical study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Prognostic impact of cathepsin B and matrix metalloproteinase-9 in pulmonary adenocarcinomas by immunohistochemical study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Extracts of human articular cartilage contain an inhibitor of tissue metalloproteinases.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Matrix metalloproteinases. Novel targets for directed cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Marimastat (BB2516): current status of development

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Matrix Metalloproteinase Inhibition as a Novel Anticancer Strategy: A Review with Special Focus on Batimastat and Marimastat

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Matrix metalloproteinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Growth factors and cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Epidermal growth factor-related peptides and their receptors in human malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

The physiology of transforming growth factor-alpha

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Autocrine growth factors and cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

ZD1839 ('Iressa') as an anticancer agent

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Inhibition of human tumor growth in nude mice by a conjugate of doxorubicin with monoclonal antibodies to epidermal growth factor receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

The p21 src genes of Harvey and Kirsten sarcoma viruses originate from divergent members of a family of normal vertebrate genes

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Nucleotide sequence of the two rat cellular rasH genes

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Three human transforming genes are related to the viral ras oncogenes

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Expression of ras proto-oncogenes: regulation and implications in the development of human tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Farnesyltransferase inhibitors versus Ras inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Inhibition of RAS-targeted prenylation: protein farnesyl transferase inhibitors revisited

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Protein prenyltransferases

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Protein prenylation: molecular mechanisms and functional consequences

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Use of yeast for identification of farnesyltransferase inhibitors and for generation of mutant farnesyltransferases

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Antisense oligonucleotides adsorbed to polyalkylcyanoacrylate nanoparticles specifically inhibit mutated Ha-ras-mediated cell proliferation and tumorigenicity in nude mice

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Farnesyl transferase inhibitors: current developments and future perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

1 reference

7 January 2021

Gene therapy for cancer: what have we done and where are we going?

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Immunologic aspects of liposomes: presentation and processing of liposomal protein and phospholipid antigens

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Improved DNA: liposome complexes for increased systemic delivery and gene expression

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Retroviral insertions downstream of the heterogeneous nuclear ribonucleoprotein A1 gene in erythroleukemia cells: evidence that A1 is not essential for cell growth

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Gene therapy for lung cancer: enhancement of tumor suppression by a combination of sequential systemic cisplatin and adenovirus-mediated p53 gene transfer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Modification of tumor suppressor gene expression and induction of apoptosis in non-small cell lung cancer (NSCLC) with an adenovirus vector expressing wildtype p53 and cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

A phase I study of adenovirus-mediated wild-type p53 gene transfer in patients with advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

In situ delivery of suicide genes for cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Gene therapy for lung disease: hype or hope?

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Human gene marker/therapy clinical protocols

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

A phase I/II study of tgAAV-CF for the treatment of chronic sinusitis in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Efficient and persistent gene transfer of AAV-CFTR in maxillary sinus

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Gene therapy for lung cancer and mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Adeno-associated virus vectors transduce primary cells much less efficiently than immortalized cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Antisense approaches for the treatment of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Modification of mutant K-ras gene expression in non-small cell lung cancer (NSCLC)

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Intracellular antibodies: development and therapeutic potential.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Monoclonal antibody therapy for solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Mitochondrion as a novel target of anticancer chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Cisplatin, epirubicin, and vindesine with or without lonidamine in the treatment of inoperable nonsmall cell lung carcinoma: a multicenter randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Cell cycle molecular targets in novel anticancer drug discovery

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Hypermethylation of the p16 (Ink4a) promoter in B6C3F1 mouse primary lung adenocarcinomas and mouse lung cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

A phase I trial of cisplatin plus decitabine, a new DNA-hypomethylating agent, in patients with advanced solid tumors and a follow-up early phase II evaluation in patients with inoperable non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

Adenovirus-mediated p16INK4a gene expression radiosensitizes non-small cell lung cancer cells in a p53-dependent manner

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900197-4

7 January 2021

10.1016/S1040-8428(01)00197-4

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11796232%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11796232%20AND%20SRC:MED&resulttype=core&format=json